GPCR modulators, as potential inhibitors of Olfr1023, represent a broad class of chemicals that interact with G-protein-coupled receptors. Given the diversity and complexity of GPCRs, these modulators offer a unique approach to indirectly influence the activity of specific receptors like Olfr1023. The chemicals listed, including beta-blockers, alpha-blockers, and angiotensin receptor antagonists, are primarily designed to target various GPCRs involved in cardiovascular, nervous, and other systemic functions. Their mode of action typically involves competitive inhibition, allosteric modulation, or receptor downregulation, which can affect the signaling pathways associated with GPCRs. In the context of olfactory receptors like Olfr1023, the indirect modulation of GPCR signaling pathways is a novel approach. While these receptors are primarily known for their role in odor detection, they are structurally similar to other GPCRs and therefore may be susceptible to the same pharmacological principles. For instance, beta-blockers like Propranolol and Metoprolol exert their effects by binding to beta-adrenergic receptors, inhibiting the action of epinephrine and norepinephrine. This results in altered GPCR signaling, which could impact other GPCRs, including olfactory receptors. Similarly, angiotensin receptor antagonists such as Losartan and Valsartan block the effects of angiotensin II, leading to changes in GPCR-mediated pathways that might influence olfactory receptor activities.
The application of these GPCR modulators to olfactory receptors like Olfr1023 is based on the understanding of GPCR biology. The potential for cross-talk between different GPCR pathways suggests that changes in the signaling dynamics of one receptor type could have repercussions on others, including olfactory receptors. This approach to modulating olfactory receptor activity, particularly in the case of Olfr1023, underscores the interconnected nature of GPCR signaling networks and offers a unique perspective on targeting specific receptor functions through indirect modulation. However, it is important to note that the specificity and direct effects of these chemicals on Olfr1023 are not well-established and would require further experimental validation.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Propranolol | 525-66-6 | sc-507425 | 100 mg | $180.00 | ||
A non-selective beta-adrenergic receptor antagonist, which can indirectly affect GPCR signaling pathways, potentially influencing Olfr1023. | ||||||
Carvedilol | 72956-09-3 | sc-200157 sc-200157A sc-200157B sc-200157C sc-200157D | 100 mg 1 g 10 g 25 g 100 g | $124.00 $240.00 $530.00 $999.00 $1530.00 | 2 | |
A non-selective beta-blocker with alpha-1 blocking activity, known to modulate GPCR activity, and may indirectly influence Olfr1023 signaling. | ||||||
(RS)-Atenolol | 29122-68-7 | sc-204895 sc-204895A | 1 g 10 g | $79.00 $416.00 | 1 | |
A selective beta1-adrenergic receptor antagonist, known to impact GPCR signaling, possibly affecting Olfr1023 indirectly. | ||||||
Losartan | 114798-26-4 | sc-353662 | 100 mg | $130.00 | 18 | |
An angiotensin II receptor antagonist that modulates GPCR activity, potentially influencing Olfr1023 indirectly. | ||||||
Valsartan | 137862-53-4 | sc-220362 sc-220362A sc-220362B | 10 mg 100 mg 1 g | $40.00 $92.00 $122.00 | 4 | |
Another angiotensin II receptor antagonist, impacting GPCR signaling and possibly affecting Olfr1023. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $374.00 | ||
A calcium channel blocker that has been shown to modulate GPCR signaling, potentially influencing Olfr1023 indirectly. | ||||||
Diltiazem | 42399-41-7 | sc-204726 sc-204726A | 1 g 5 g | $209.00 $464.00 | 4 | |
A calcium channel blocker which can affect GPCR signaling pathways, potentially impacting Olfr1023 activity. | ||||||
Yohimbine hydrochloride | 65-19-0 | sc-204412 sc-204412A sc-204412B | 1 g 5 g 25 g | $51.00 $171.00 $530.00 | 2 | |
An alpha-2 adrenergic receptor antagonist that modulates GPCR signaling, possibly affecting Olfr1023 indirectly. | ||||||
Rauwolscine • HCl | 6211-32-1 | sc-200151 | 100 mg | $107.00 | ||
Similar to Yohimbine, an alpha-2 adrenergic receptor antagonist that could indirectly influence Olfr1023 through GPCR signaling modulation. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
A non-selective beta-adrenergic agonist, which modulates GPCR activity and could indirectly affect Olfr1023 signaling. | ||||||